HealthMore in Health→
Eli Lilly’s CrossBridge Bio deal keeps oncology dealmaking focused on smaller, targeted bets
Eli Lilly’s agreement to acquire CrossBridge Bio for up to $300 million highlights continued appetite for targeted oncology assets, even at the small-company end of biotech dealmaking.
Key Takeaways
- Endpoints reported Eli Lilly will acquire CrossBridge Bio for up to $300 million.
- CrossBridge Bio is described as a small Houston startup focused on antibody-drug conjugates.
DE
DT Editorial Team··via endpoints.news